Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

Status: open

17-116: DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (S1609)

Treatment for Rare Tumors

Contact Us Or call (251) 665-8000

Description

PRIMARY OBJECTIVES:

I. To evaluate the Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 overall response rate (ORR) in subsets of patients with advanced rare cancers treated with ipilimumab plus nivolumab combination immunotherapy.

SECONDARY OBJECTIVES:

I. To evaluate toxicities in each cohort. II. To estimate overall survival (OS), progression-free survival (PFS), clinical benefit rate; and to estimate immune-related ORR (irORR), and immune-related PFS (irPFS) by unidimensional immune-related response criteria.

After completion of study treatment, patients are followed up for 10 years from registration.

Sponsors

This trial is sponsored by SWOG.

Providers Associated With This Trial

Principle Investigator

Sub Investigators

This link will open in a new tab or window.